BioNTech SE (Nasdaq: NASDAQ:BNTX) and OncoC4, Inc. (“OncoC4”), today announced positive preliminary data from the ongoing Phase 1/2 trial with the companies’ anti-CTLA-4 antibody candidate,...
An analyst from H.C. Wainwright maintained BioNTech (NASDAQ: BNTX) at 'buy' with a price target of $181.00 from a prior price target of $198.00. Prior to this rating, BioNTech had 10 buy...
An analyst from H.C. Wainwright maintained BioNTech (NASDAQ: BNTX) at 'buy' with a price target of $198.00 from a prior price target of $210.00. Prior to this rating, BioNTech had 10 buy...
An analyst from Redburn upgraded BioNTech (NASDAQ: BNTX) from 'neutral' to 'buy' with a price target of $170.00 from a prior price target of $165.00. Prior to this rating, BioNTech had 9...
An analyst from Berenberg maintained BioNTech (NASDAQ: BNTX) at to 'buy' and a price target of $200.00 from a prior price target of $260.00. Prior to this rating, BioNTech had 9 buy...
An analyst from TD Cowen maintained BioNTech (NASDAQ: BNTX) to 'market perform' and a price target of $109.00 from a prior price target of $130.00. Prior to this rating, BioNTech had 9...
Investing.com - BioNTech (NASDAQ: BNTX) reported first quarter EPS of €2.05, €1.90 better than the analyst estimate of €0.15. Revenue for the quarter came in at €1.28B...
A BofA Securities analyst maintained BioNTech (NASDAQ: BNTX) at Buy and a price target of $181.00 from a prior price target of $194.00. Prior to this rating, BioNTech had 9 buy ratings, 8...
A Deutsche Bank analyst maintained BioNTech (NASDAQ: BNTX) at Hold and a price target of $135.00 from a prior price target of $160.00. Prior to this rating, BioNTech had 9 buy ratings, 8...
Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna (NASDAQ:MRNA) and Pfizer-BioNTech COVID-19 bivalent mRNA vaccines to simplify...
A JPMorgan analyst maintained BioNTech (NASDAQ: BNTX) at Neutral and a price target of $128.00 from a prior price target of $145.00. Prior to this rating, BioNTech had 9 buy ratings, 8...
Arbutus Biopharma (NASDAQ:ABUS) Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics...
An UBS analyst maintained BioNTech (NASDAQ: BNTX) at Neutral and a price target of $153.00 from a prior price target of $168.00. Prior to this rating, BioNTech had 8 buy ratings, 7 hold...
By Sam Boughedda Morgan Stanley analysts named BioNTech SE (NASDAQ:BNTX) a Catalyst Driven Idea in a note to clients Thursday. The analysts, who have an Equal-weight rating and a $150 price...
A Morgan Stanley analyst maintained BioNTech (NASDAQ: BNTX) at Equalweight and a price target of $150.00. Prior to this rating, BioNTech had 8 buy ratings, 7 hold ratings, and 0 sell...
BioNTech SE (Nasdaq: BNTX) today announced that it has entered into a new share repurchase program (the “Program”), pursuant to which the Company may purchase American Depositary Shares,...
A Goldman Sachs analyst maintained BioNTech (NASDAQ: BNTX) at Neutral and a price target of $140.00 from a prior price target of $156.00. Prior to this rating, BioNTech had 8 buy ratings,...
By Liz Moyer Investing.com -- Stocks were mostly higher as banks helped lift the indexes, though rising Treasury yields weighed on tech stocks. Here are the midday movers for March...
By Liz Moyer Investing.com -- U.S. stocks were rising as banking stocks regained ground after the weekend deal for deposits and assets of Silicon Valley Bank. At 9:54 ET (13:54 GMT), the Dow...
By Senad Karaahmetovic BioNTech (NASDAQ:BNTX) reported better-than-expected results for its first quarter although its guidance for COVID-19 vaccine sales came in significantly lower than...
Investing.com - BioNTech (NASDAQ: BNTX) reported first quarter EPS of €9.26, €1.14 better than the analyst estimate of €8.12. Revenue for the quarter came in at €4.28B...
BioNTech SE (Nasdaq: NASDAQ:BNTX) today announced that they have entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4’s...
Pfizer Inc. (PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose...
Pfizer Inc. (NYSE:PFE) and BioNTech SE (Nasdaq: NASDAQ:BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
By Geoffrey Smith Investing.com -- Two key lieutenants of Sam Bankman-Fried entered guilty pleas and said they will cooperate with the investigation against their former boss/boyfriend. The...
By Sam Boughedda BofA analysts upgraded BioNTech SE (NASDAQ:BNTX) to Buy from Neutral, maintaining a $239 price target on the stock in a note to clients Thursday. The upgrade is due to...
By Liz Moyer Investing.com -- Stocks were rising on Thursday as investors tried to break the S&P 500's five-day losing streak ahead of next week's Fed meeting. Here are the midday movers for...
By Davit Kirakosyan JPMorgan lowered the price target on Take-Two Interactive (NASDAQ:TTWO) to $144.00 from $165.00 while maintaining an Overweight rating. Shares fell more than 13% today...
By Liz Moyer Investing.com -- Stocks were rising as investors awaited the outcome of the midterm elections, and the answer to which party will control Congress. Here are the midday movers...
By Scott Kanowsky Investing.com -- BioNTech SE (22UAy) has raised its guidance for annual revenues from COVID-19 vaccines, citing continued shipments of Omicron booster shots, higher prices...
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Monday, November 7th. Please refresh for updates. Apple (NASDAQ:AAPL) stock fell 1.6% after the iPhone maker warned of...
By Peter Nurse Investing.com -- U.S. stocks are seen edging higher at the open Monday, starting the week on a positive note ahead of potentially significant U.S. midterm elections and the...
BioNTech SE (BNTX) reported Q3 EPS of EUR6.98. Revenue for the quarter came in at EUR3.45 billion.
By Senad Karaahmetovic Shares of Moderna (NASDAQ:MRNA) are up over 1% after a Deutsche Bank analyst upgraded shares to Buy from Hold with a $165 per share price target. The analyst took...
By Yasin Ebrahim Investing.com -- The Dow closed sharply lower Friday, driven by a meltdown in tech after Federal Reserve chairman Jerome Powell signaled that higher for longer interest...
By Yasin Ebrahim Investing.com -- The S&P 500 slumped Friday, driven by a meltdown in tech after Federal Reserve chairman Jerome Powell signaled that higher for longer interest rates would...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
